Supplementary materials

Functional validation of somatic variability in *TP53* and *KRAS* for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients

Mohammad Al Obeed Allah[1], Esraa Alli[1], Ivona Krus[2], Petr Holý[1,2], Vojtěch Haničinec[1], Filip Ambrozkiewicz[1], Lukáš Rob[3], Martin Hruda[3], Marcela Mrhalová[4], Kateřina Kopečková[5], Alena Bartáková[6], Jiří Bouda[6], Pavel Souček[1,2], and Radka Václavíková[1,2]*

[1]Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic;

[2]Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic;

[3]Department of Gynecology and Obstetrics, Third Faculty of Medicine, Charles University and University Hospital Královské Vinohrady, Prague, Czech Republic;

[4]Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic;

[5]Department of Oncology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic;

[6]Department of Gynecology and Obstetrics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.

*Correspondence: Radka Václavíková, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen 306 05, Czech Republic; email: radka.vaclavikova@lfp.cuni.cz, phone: +420 267 082 711; ORCID: 0000-0002-0451-4725

List of supplementary materials

Figure S1: Associations between stage (A), residuum after surgery (B), and chemosensitivity status (C) and overall survival of EOC patients

Figure S2: Representative chromatograms of *KRAS* mutations assessed in EOC patients by direct Sanger sequencing

A – codon 12 in exon 2, B – codon 61 in exon 3

Figure S3: Representative chromatograms of *TP53* mutations assessed in EOC patients by direct Sanger sequencing

A – p.Arg175His, B – p.His179Gln, C – p.His214Arg, D – p.Tyr220Cys, E – p.Glu198Ter, F – p.Arg213Ter, G – p.Asp259Tyr, H – p.Arg273His, I – p.Arg282Trp, J – p.Arg248His/Trp.

Figure S4: Differences in TP53 transcript levels between patients divided by functional classifications of *TP53* mutations

Gain-of-function vs. loss-of-function (A), non-functional vs. functional transactivation (B), and DNA binding loop affecting vs. other (C)

Figure S5: Association between subtype and platinum-free (A) and overall (B) survival of EOC patients

Figure S6: Association between *TP53* mutation status and platinum-free interval of nonHGSC EOC patients

Table S1: List of primers used for *KRAS* and *TP53* mutation analysis in EOC patients by direct Sanger sequencing

Table S2: Associations between EOC subtype and disease stage

Figure S1: Associations between stage (A), residuum after surgery (B), and chemosensitivity status (C) and overall survival of EOC patients



Figure S2: Representative chromatograms of *KRAS* mutations assessed in EOC patients by direct Sanger sequencing

A – codon 12 in exon 2, B – codon 61 in exon 3



Figure S3: Representative chromatograms of *TP53* mutations assessed in EOC patients by direct Sanger sequencing

A – p.Arg175His, B – p.His179Gln, C – p.His214Arg, D – p.Tyr220Cys, E – p.Glu198Ter, F – p.Arg213Ter, G – p.Asp259Tyr, H – p.Arg273His, I – p.Arg282Trp, J – p.Arg248His/Trp.




E
wild type
p.Glu198Ter
F
wild type
p. Arg213Ter
G
wild type
p.Asp259Tyr
H
wild type
p.Arg273His

I


wild type
p.Arg282Trp

J


wild type
wild type
p.Arg248Gln
p.Arg248Trp

Figure S4: Differences in TP53 transcript levels between patients divided by functional classifications of *TP53* mutations
Gain-of-function vs. loss-of-function (A), non-functional vs. functional transactivation (B), and DNA binding loop affecting vs. other (C)



Figure S5: Association between subtype and platinum-free (A) and overall (B) survival of EOC patients



Figure S6: Association between *TP53* mutation status and platinum-free interval of nonHGSC EOC patients



Table S1: List of primers used for *KRAS* and *TP53* mutation analysis in EOC patients by direct Sanger sequencing

Gene	**Exon**	**Sequencing primers (5'->3')**	
		Forward	Reverse
TP53			
	5	CACTTGTGCCCTGACTTTCA	AGAGACGACAGGGCTGGTT
	6	CAGGCCTCTGATTCCTCACT	CTCTGGGAGGAGGGGTTAAG
	7	CCACAGGTCTCCCCAAGG	CTGCACACTGGCCTGCTG
	8	GCCTCTTGCTTCTCTTTTCC	GGAGACCAAGGGTGCAGTTA
	9	AGCACTAAGCGAGGTAAGCA	CCAGGAGCCATTGTCTTTGA
	10	TGCATGTTGCTTTTGTACCGT	GGCTGGGACCCAATGAGAT
KRAS			
	2	AAGCGTCGATGGAGGAGTTT	GAATGGTCCTGCACCAGTAAT
	3	AGGTGCACTGTAATAATCCAGACT	TGCATGGCATTAGCAAAGACTC

Table S2: Associations between EOC subtype and disease stage

Characteristics	**HGSC subtype***	**nonHGSC subtypes***	**p-value**
Stage I/II	13	13	<0.001
Stage III/IV	132	8	

Footnotes:
*Numbers of patients; for some patients clinical data were not available.